Nature Reviews Drug Discovery

Upcoming FDA approval decisions in Q4 2025

Kaniaw Dilzer Oct 01, 2025 pp. 735-735 10.1038/d41573-025-00152-5

New US$3.1 billion foundation takes big, long-term bets on bioscience, AI and the environment

Asher Mullard Oct 01, 2025 pp. 736-737 10.1038/d41573-025-00154-3

Breakthrough therapy designations in China and the United States

Xiangyun Mao, Yi Li, Aaron S. Kesselheim et al. Oct 01, 2025 pp. 733-734 10.1038/d41573-025-00153-4

Novel drug candidates for hard-to-treat hypertension vie for blockbuster positioning

Asher Mullard Oct 01, 2025 pp. 731-731 10.1038/d41573-025-00150-7

FDA approves anti-prekallikrein drug for hereditary angioedema

Asher Mullard Oct 01, 2025 pp. 732-732 10.1038/d41573-025-00151-6

First protease activator secures FDA approval for rare brain cancer

Asher Mullard Oct 01, 2025 pp. 730-730 10.1038/d41573-025-00148-1

AbbVie bets on psychedelic drugs in Gilgamesh buy out

Asher Mullard Oct 01, 2025 pp. 732-732 10.1038/d41573-025-00149-0

Towards a broad-spectrum antiviral agent

Sarah Crunkhorn Oct 01, 2025 pp. 742-742 10.1038/d41573-025-00145-4

Combination therapy alleviates AD-related pathologies

Sarah Crunkhorn Oct 01, 2025 pp. 742-742 10.1038/d41573-025-00146-3

Potentiating the integrated stress response

Sarah Crunkhorn Oct 01, 2025 pp. 742-742 10.1038/d41573-025-00147-2

Prime editing treats childhood neurological disease

Sarah Crunkhorn Oct 01, 2025 pp. 742-742 10.1038/d41573-025-00144-5

Soluble Notch agonists drive T cell production

M. Teresa Villanueva Oct 01, 2025 pp. 741-741 10.1038/d41573-025-00143-6

Epigenetic inhibitor silences KRAS-driven oncogenes

Alex Eccleston Oct 01, 2025 pp. 740-740 10.1038/d41573-025-00142-7

Gut microbiota–derived metabolite drives atherosclerosis

Sarah Crunkhorn Oct 01, 2025 pp. 741-741 10.1038/d41573-025-00141-8

Transport vehicle delivers antibodies to the brain

Katie Kingwell Oct 01, 2025 pp. 740-740 10.1038/d41573-025-00140-9

Neutrophil-targeted drug secures first FDA approval for inflammatory lung disease

Katie Kingwell Oct 01, 2025 pp. 729-729 10.1038/d41573-025-00135-6

The rise of China’s pharmaceutical industry from 2015–2024: a decade of innovation

Sen Liu, Hongxi Hu, Chenghao Ge et al. Oct 01, 2025 pp. 738-739 10.1038/d41573-025-00102-1

Metabolites as agents and targets for cancer immunotherapy 

Marcel P. Trefny, Guido Kroemer, Laurence Zitvogel et al. Oct 01, 2025 pp. 764-784 10.1038/s41573-025-01227-z

Targeting DNA damage in ageing: towards supercharging DNA repair

Arturo Bujarrabal-Dueso, George A. Garinis, Paul D. Robbins et al. Oct 01, 2025 pp. 785-807 10.1038/s41573-025-01212-6

Targeting protein disorder: the next hurdle in drug discovery

Tamas Lazar, Acadia Connor, Charles F. DeLisle et al. Oct 01, 2025 pp. 743-763 10.1038/s41573-025-01220-6

Innovative Medicines Initiative public–private partnerships to enhance translational safety

Salah-Dine Chibout, Dominique Brees, Magda Chlebus et al. Oct 01, 2025 pp. 727-728 10.1038/d41573-025-00080-4